These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33470669)

  • 21. Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study.
    Knorr U; Simonsen AH; Jensen CS; Zetterberg H; Blennow K; Akhøj M; Forman J; Hasselbalch SG; Kessing LV
    J Affect Disord; 2022 Jan; 297():623-633. PubMed ID: 34728295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe.
    Iaccarino L; Burnham SC; Dell'Agnello G; Dowsett SA; Epelbaum S
    J Prev Alzheimers Dis; 2023; 10(3):426-442. PubMed ID: 37357283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
    Leuzy A; Mattsson-Carlgren N; Cullen NC; Stomrud E; Palmqvist S; La Joie R; Iaccarino L; Zetterberg H; Rabinovici G; Blennow K; Janelidze S; Hansson O
    Alzheimers Dement; 2023 Jul; 19(7):2994-3004. PubMed ID: 36681387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
    Kurz C; Stöckl L; Schrurs I; Suridjan I; Gürsel SÜ; Bittner T; Jethwa A; Perneczky R
    J Neurochem; 2023 Apr; 165(1):95-105. PubMed ID: 36625424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease.
    Palmqvist S; Insel PS; Stomrud E; Janelidze S; Zetterberg H; Brix B; Eichenlaub U; Dage JL; Chai X; Blennow K; Mattsson N; Hansson O
    EMBO Mol Med; 2019 Dec; 11(12):e11170. PubMed ID: 31709776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.
    Stevenson-Hoare J; Heslegrave A; Leonenko G; Fathalla D; Bellou E; Luckcuck L; Marshall R; Sims R; Morgan BP; Hardy J; de Strooper B; Williams J; Zetterberg H; Escott-Price V
    Brain; 2023 Feb; 146(2):690-699. PubMed ID: 35383826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of kidney function and CSF/serum albumin ratio on plasma Aβ42 and Aβ40 levels measured on a fully automated platform in patients with Alzheimer's disease.
    Verde F; Milone I; Dubini A; Colombrita C; Perego A; Solca F; Maranzano A; Ciusani E; Poletti B; Ratti A; Torresani E; Silani V; Ticozzi N
    Neurol Sci; 2023 Sep; 44(9):3287-3290. PubMed ID: 37284933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology.
    Shir D; Mielke MM; Hofrenning EI; Lesnick TG; Knopman DS; Petersen RC; Jack CR; Algeciras-Schimnich A; Vemuri P; Graff-Radford J
    J Alzheimers Dis; 2023; 92(3):887-898. PubMed ID: 36806507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical application of optimized AT(N) classification in Alzheimer's clinical syndrome (ACS) and non-ACS conditions.
    Kasuga K; Tsukie T; Kikuchi M; Tokutake T; Washiyama K; Shimizu S; Yoshizawa H; Kuroha Y; Yajima R; Mori H; Arakawa Y; Onda K; Miyashita A; Onodera O; Iwatsubo T; Ikeuchi T;
    Neurobiol Aging; 2023 Jul; 127():23-32. PubMed ID: 37030016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
    Milà-Alomà M; Salvadó G; Gispert JD; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
    Alzheimers Dement; 2020 Oct; 16(10):1358-1371. PubMed ID: 32573951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sexually Dimorphic Association of Circulating Plasminogen Activator Inhibitor-1 Levels and Body Mass Index with Cerebrospinal Fluid Biomarkers of Alzheimer's Pathology in Preclinical Alzheimer's Disease.
    Eruysal E; Ravdin L; Zhang C; Kamel H; Iadecola C; Ishii M
    J Alzheimers Dis; 2023; 91(3):1073-1083. PubMed ID: 36565112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease.
    Peña-Bautista C; Álvarez-Sánchez L; Pascual R; Moreno MJ; Baquero M; Cháfer-Pericás C
    Eur J Clin Invest; 2023 Mar; 53(3):e13910. PubMed ID: 36401799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.